Gold Silver Reports (GSR) – Dr. Reddy’s Lab Gains After FDA Inspection Concludes – Shares of the drugmaker rose as much as 3.8 percent to Rs 2,013.85. The U.S drug regulator concluded inspection at the pharmaceutical company’s Srikakulam Plant with no observations.
Dr Reddy
Dr Reddy’s Labs Gains On Receiving EIR From U.S. FDA; Diamond Power Infra Slumps After ED Attaches Properties Worth Rs 1,120 Crore
Dr Reddy’s Labs Gains On Receiving EIR From U.S. FDA – Shares of the Hyderabad-based rug maker rose 0.8 percent to Rs 2,152. Dr Reddy’s Labs informed exchanges that it has received Establishment Inspection Report (EIR) from U.S. FDA for its Mirfield plant in UK.
Dr Reddy’s Labs Gains After U.S. Unit Files NDA For Migraine Drug
Dr Reddy’s Labs Gains After U.S. Unit Files NDA For Migraine Drug — Shares of the Hyderabad-based drug maker rose as much as 2.6 percent to Rs 2,135 after its U.S. subsidiary Promius Pharma filed for New Drug Application (NDA) for its migraine candidate.